Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2012 2
2013 4
2014 3
2016 1
2017 2
2018 4
2019 6
2020 4
2021 9
2022 6
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: guger m. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Month-of-birth-effect in multiple sclerosis in Austria.
Walleczek NK, Frommlet F, Bsteh G, Eggers C, Rauschka H, Koppi S, Assar H, Ehling R, Birkl C, Salhofer-Polanyi S, Baumgartner A, Blechinger S, Buchinger D, Sellner J, Kraus J, Moser H, Mayr M, Guger M, Rathmaier S, Raber B, Liendl H, Hiller MS, Parigger S, Morgenstern G, Kempf I, Spiss HK, Meister B, Heine M, Cisar A, Bachler H, Khalil M, Fuchs S, Enzinger C, Fazekas F, Leutmezer F, Berger T, Kristoferitsch W, Aboulenein-Djamshidian F. Walleczek NK, et al. Among authors: guger m. Mult Scler. 2019 Dec;25(14):1870-1877. doi: 10.1177/1352458518810924. Epub 2018 Nov 22. Mult Scler. 2019. PMID: 30463473
Epidemiology of Multiple Sclerosis in Austria.
Salhofer-Polanyi S, Cetin H, Leutmezer F, Baumgartner A, Blechinger S, Dal-Bianco A, Altmann P, Bajer-Kornek B, Rommer P, Guger M, Leitner-Bohn D, Reichardt B, Alasti F, Temsch W, Stamm T. Salhofer-Polanyi S, et al. Among authors: guger m. Neuroepidemiology. 2017;49(1-2):40-44. doi: 10.1159/000479696. Epub 2017 Aug 19. Neuroepidemiology. 2017. PMID: 28848208
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Hunter ZR, Kallmann B, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber MS, Weber F, Zettl UK, Ziemssen T, Zipp F; die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). Wiendl H, et al. Among authors: guger m. Nervenarzt. 2021 Aug;92(8):773-801. doi: 10.1007/s00115-021-01157-2. Epub 2021 Jul 23. Nervenarzt. 2021. PMID: 34297142 Free PMC article. Review. German.
Impact of vaccination on COVID-19 outcome in multiple sclerosis.
Bsteh G, Gradl C, Heschl B, Hegen H, Di Pauli F, Assar H, Leutmezer F, Traxler G, Krajnc N, Zulehner G, Hiller MS, Rommer P, Wipfler P, Guger M, Enzinger C, Berger T; AUT-MuSC investigators. Bsteh G, et al. Among authors: guger m. Eur J Neurol. 2022 Jul 5:10.1111/ene.15488. doi: 10.1111/ene.15488. Online ahead of print. Eur J Neurol. 2022. PMID: 35791496 Free PMC article.
Real-life use of oral disease-modifying treatments in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Acta Neurol Scand. 2019 Jul;140(1):32-39. doi: 10.1111/ane.13097. Epub 2019 Apr 22. Acta Neurol Scand. 2019. PMID: 30958901 Free PMC article.
Caregiver strain in progressive supranuclear palsy and corticobasal syndromes.
Kellermair L, Fuchs A, Eggers C, Schwingenschuh P, Kögl M, Fellner F, Forstner T, Mangesius S, Guger M, Ransmayr G. Kellermair L, et al. Among authors: guger m. J Neural Transm (Vienna). 2021 Oct;128(10):1611-1621. doi: 10.1007/s00702-021-02379-z. Epub 2021 Jul 22. J Neural Transm (Vienna). 2021. PMID: 34296340 Free PMC article.
Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study.
Seifert-Held T, Eberhard K, Lechner C, Macher S, Hegen H, Moser T, Jacob GB, Puttinger G, Topakian R, Guger M, Kacar E, Zoche L, De Simoni D, Seiser A, Oberndorfer S, Baumgartner C, Struhal W, Zimprich F, Sellner J, Deisenhammer F, Enzinger C, Reindl M, Rauschka H, Berger T, Höftberger R. Seifert-Held T, et al. Among authors: guger m. Front Immunol. 2021 May 21;12:641106. doi: 10.3389/fimmu.2021.641106. eCollection 2021. Front Immunol. 2021. PMID: 34093529 Free PMC article.
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
Monschein T, Dekany S, Zrzavy T, Ponleitner M, Altmann P, Bsteh G, Kornek B, Rommer P, Enzinger C, Di Pauli F, Kraus J, Berger T, Leutmezer F, Guger M; Austrian MS Treatment Registry (AMSTR). Monschein T, et al. Among authors: guger m. J Neurol. 2023 Aug;270(8):3787. doi: 10.1007/s00415-023-11784-1. J Neurol. 2023. PMID: 37272963 Free PMC article. No abstract available.
41 results